Bioporto A/S

View in Terminal

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, Bioporto A/S had revenue of €923.4k and net profit of €4.81m

(EUR)	June 2026	YoY
Revenue	923.4k	34.95%
Gross profit	573.68k	39.39%
Net profit	4.81m	298.54%
EBITDA	-2.51m	6.72%

Fundamentals

Metric	Value
Market capitalization	€67.57m
Number of shares	495.1m
52-week high/low	€0.18 - €0.11
Dividends	No
Beta	1.35
P/E ratio	76.63
PEG ratio	0.35
P/B ratio	6.13
P/S ratio	13.61

Company profile

BioPorto A/S, an in-vitro diagnostics company, provides diagnostic tests and antibodies to clinicians and researchers worldwide. The company offers the neutrophil gelatinase-associated lipocalin test, a particle-enhanced turbidimetric test that measures NGAL that is used to supplement clinical evaluation and standard tests; monoclonal antibodies for scientific, pharmaceutical, and clinical research use; enzyme-linked immunosorbent assay kits; IVD automated assays; and generic rapid assay device platform for the development of lateral flow assays. It sells its products through own sales team, distributors, and OEM partnerships. The company was founded in 2000 and is headquartered in Hellerup, Denmark.